Deutsche Bank today maintained a Buy rating on Biogen (NASDAQ: BIIB) with a price target to $240.00. Deutsche Bank also ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE